HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions.

AbstractBACKGROUND AND PURPOSE:
Iron oxide-based contrast agents have been investigated as more specific MR imaging agents for central nervous system (CNS) inflammation. Ferumoxtran-10 is a virus-size nanoparticle, taken up by reactive cells, that allows visualization of the phagocytic components of CNS lesions. Ferumoxtran-10 was compared with standard gadolinium-enhanced MR images in this exploratory trial to assess its potential in evaluation of CNS lesions with inflammatory aspects, including lymphoma, multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and vascular lesions.
METHODS:
Twenty-three patients with different types of intracranial "inflammatory" lesions underwent standard brain MR with and without gadolinium, followed an average of 10 days later by a ferumoxtran-10 scan. Patients were imaged 24 hours after infusion of 2.6 mg/kg ferumoxtran-10. All MR images were evaluated subjectively by 4 investigators for a difference in enhancement patterns, which could be useful in differential diagnoses.
RESULTS:
In 5 cases, (one ADEM, 2 stroke, one cavernous venous vascular malformation, one primary central nervous lymphoma) the ferumoxtran-10 scan showed higher signal intensity, larger area of enhancement, or new enhancing areas compared with gadolinium. Most MS patients showed less enhancement with ferumoxtran-10 than with gadolinium.
CONCLUSION:
Ferumoxtran-10 showed different enhancement patterns in a variety of CNS lesions with inflammatory components in comparison to gadolinium. The impact of timing and therapy need further evaluation to better assess ferumoxtran-10 in addition to gadolinium as contrast agents for use in diagnosis and monitoring therapy in patients with CNS inflammatory lesions.
AuthorsSándor P Manninger, Leslie L Muldoon, Gary Nesbit, Tulio Murillo, Paula M Jacobs, Edward A Neuwelt
JournalAJNR. American journal of neuroradiology (AJNR Am J Neuroradiol) Vol. 26 Issue 9 Pg. 2290-300 (Oct 2005) ISSN: 0195-6108 [Print] United States
PMID16219835 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Contrast Media
  • Dextrans
  • Magnetite Nanoparticles
  • Oxides
  • ferumoxtran-10
  • gadodiamide
  • Iron
  • Gadolinium DTPA
  • Ferrosoferric Oxide
Topics
  • Adolescent
  • Adult
  • Aged
  • Blood-Brain Barrier (physiopathology)
  • Brain (pathology)
  • Brain Neoplasms (diagnosis, pathology)
  • Central Nervous System Diseases (diagnosis, pathology)
  • Cerebrovascular Disorders (diagnosis, pathology)
  • Contrast Media
  • Demyelinating Diseases (diagnosis, pathology)
  • Dextrans
  • Female
  • Ferrosoferric Oxide
  • Gadolinium DTPA
  • Humans
  • Inflammation
  • Iron
  • Magnetic Resonance Imaging
  • Magnetite Nanoparticles
  • Male
  • Middle Aged
  • Nanostructures
  • Oxides
  • Phagocytes (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: